139 related articles for article (PubMed ID: 28702647)
1. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.
Huang X; Zhuang C; Zhuang C; Xiong T; Li Y; Gui Y
Mol Biosyst; 2017 Aug; 13(9):1713-1721. PubMed ID: 28702647
[TBL] [Abstract][Full Text] [Related]
2. Synthetic regulatory RNAs selectively suppress the progression of bladder cancer.
Zhuang C; Huang X; Zhuang C; Luo X; Zhang X; Cai Z; Gui Y
J Exp Clin Cancer Res; 2017 Oct; 36(1):151. PubMed ID: 29084575
[TBL] [Abstract][Full Text] [Related]
3. Synthetic miRNA sponges driven by mutant hTERT promoter selectively inhibit the progression of bladder cancer.
Zhuang CL; Fu X; Liu L; Liu YC; Huang WR; Cai ZM
Tumour Biol; 2015 Jul; 36(7):5157-63. PubMed ID: 25775949
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer.
Liu L; Liu Y; Zhang T; Wu H; Lin M; Wang C; Zhan Y; Zhou Q; Qiao B; Sun X; Zhang Q; Guo X; Zhao G; Zhang W; Huang W
J Exp Clin Cancer Res; 2016 Jan; 35():3. PubMed ID: 26743236
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer.
Zhen S; Hua L; Liu YH; Sun XM; Jiang MM; Chen W; Zhao L; Li X
Oncotarget; 2017 Feb; 8(6):9634-9646. PubMed ID: 28038452
[TBL] [Abstract][Full Text] [Related]
6. Expression of a recombinant vector of a mutant human telomerase reverse transcriptase gene in human bladder cancer cell line T24, and its clinical significance.
Fu WJ; Hong BF; Huang JJ; Xu B; Gao JP; Wang XX; Huang CF
BJU Int; 2005 Oct; 96(6):890-4. PubMed ID: 16153224
[TBL] [Abstract][Full Text] [Related]
7. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.
Agarwal N; Rinaldetti S; Cheikh BB; Zhou Q; Hass EP; Jones RT; Joshi M; LaBarbera DV; Knott SRV; Cech TR; Theodorescu D
Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34518220
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the growth of melanoma cells via hTERT gene editing using CRISPR-dCas9-dnmt3a system.
Rad FT; Gargari BN; Ghorbian S; Farsani ZS; Sharifi R
Gene; 2022 Jun; 828():146477. PubMed ID: 35398175
[TBL] [Abstract][Full Text] [Related]
9. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells.
Liu Y; Zeng Y; Liu L; Zhuang C; Fu X; Huang W; Cai Z
Nat Commun; 2014 Nov; 5():5393. PubMed ID: 25373919
[TBL] [Abstract][Full Text] [Related]
10. Engineered CRISPR/Cas13d Sensing hTERT Selectively Inhibits the Progression of Bladder Cancer
Zhuang C; Zhuang C; Zhou Q; Huang X; Gui Y; Lai Y; Yang S
Front Mol Biosci; 2021; 8():646412. PubMed ID: 33816560
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide screens identify specific drivers of mutant
Shanmugam R; Ozturk MB; Low JL; Akincilar SC; Chua JYH; Thangavelu MT; Periyasamy G; DasGupta R; Tergaonkar V
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35027447
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 with single guide RNA expression driven by small tRNA promoters showed reduced editing efficiency compared to a U6 promoter.
Wei Y; Qiu Y; Chen Y; Liu G; Zhang Y; Xu L; Ding Q
RNA; 2017 Jan; 23(1):1-5. PubMed ID: 27742910
[TBL] [Abstract][Full Text] [Related]
13. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
[TBL] [Abstract][Full Text] [Related]
14. Targeting RLIP with CRISPR/Cas9 controls tumor growth.
Singhal J; Chikara S; Horne D; Awasthi S; Salgia R; Singhal SS
Carcinogenesis; 2021 Feb; 42(1):48-57. PubMed ID: 32426802
[TBL] [Abstract][Full Text] [Related]
15. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells.
Deng WG; Jayachandran G; Wu G; Xu K; Roth JA; Ji L
J Biol Chem; 2007 Sep; 282(36):26460-70. PubMed ID: 17630431
[TBL] [Abstract][Full Text] [Related]
17. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.
Xue Y; Li L; Zhang D; Wu K; Chen Y; Zeng J; Wang X; He D
PLoS One; 2011; 6(11):e27748. PubMed ID: 22110753
[TBL] [Abstract][Full Text] [Related]
18. Production and Validation of Lentiviral Vectors for CRISPR/Cas9 Delivery.
Ryø LB; Thomsen EA; Mikkelsen JG
Methods Mol Biol; 2019; 1961():93-109. PubMed ID: 30912042
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
Zhen S; Lu J; Chen W; Zhao L; Li X
Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
[TBL] [Abstract][Full Text] [Related]
20. Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Zhang N; Zhao L; Ma S; Gu M; Zheng X
Int J Mol Med; 2012 Sep; 30(3):659-65. PubMed ID: 22710559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
